HMGN5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This product features targeted disruption of the HMGN5 gene, which encodes a nucleosome-binding protein that regulates chromatin structure and gene expression. The polyclonal pool enables loss-of-function studies in a heterogeneous cell population, ideal for robust functional genomics analyses.
The A-549 host cell line was established from a lung adenocarcinoma of a 58-year-old male and displays alveolar type II epithelial characteristics. It harbors a KRAS mutation, a prevalent oncogenic driver in non-small cell lung cancer. A-549 cells are a benchmark model for investigating lung adenocarcinoma biology, including proliferation, migration, and therapeutic resistance.
HMGN5 decompacts chromatin to facilitate transcription of genes involved in cell proliferation and survival. It is regulated by upstream factors such as MYC, E2F1, and the Wnt/??-catenin pathway, and is post-transcriptionally repressed by miR-142-3p. Downstream, HMGN5 promotes expression of CCND1, MMP9, BCL2, and SNAI1, which drive cell cycle progression, invasion, anti-apoptosis, and epithelial-mesenchymal transition. HMGN5 interacts with p53, LEF1, histone H3, and the SWI/SNF chromatin remodeling complex, functionally integrating Wnt/??-catenin, PI3K/Akt, and MAPK/ERK signaling cascades. Through these interactions, HMGN5 acts as a critical node sustaining pro-tumorigenic transcriptional programs.
In the A-549 context, HMGN5 knockout disrupts chromatin accessibility at target promoters, attenuating Wnt/??-catenin and PI3K/Akt signaling. This results in reduced transcriptional output from ??-catenin/TCF4/LEF1 complexes and diminished AKT phosphorylation, leading to decreased cell proliferation, increased apoptosis, and impaired migration. The model thus provides a valuable system for examining chromatin-mediated oncogenic mechanisms in lung adenocarcinoma and for screening potential therapeutic interventions.
These polyclonal knockout cells are suitable for applications including chromatin biology in cancer, lung adenocarcinoma progression, drug resistance mechanisms, and Wnt/??-catenin pathway regulation. Representative experiments encompass Western blotting for HMGN5 and targets like CCND1 and MMP9, RT-qPCR, transcriptomic profiling via RNA-seq, chromatin accessibility mapping by ChIP-seq, MTT proliferation analysis, Annexin V apoptosis detection, transwell migration evaluation, and Wnt reporter assays. The heterogeneous knockout population ensures consistent functional studies free from clonal selection bias. For additional technical information, please contact Ascent Research.
